Cellectar Biosciences Inc.(CLRB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CLRB Cellectar Biosciences Inc.

交易中 07-31 14:01:46 EDT

2.57

+0.04

+1.59%

最高2.60	最低2.51	成交量2.24万
今开2.60	昨收2.53	日振幅3.56%
总市值2,054万	流通市值1,997万	总股本799.18万
成交额5.72万	换手率0.29%	流通股本776.79万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CLRB","market":"US","secType":"STK","nameCN":"Cellectar Biosciences Inc.","latestPrice":2.5703,"timestamp":1785520712843,"preClose":2.53,"halted":0,"volume":22419,"delay":0,"changeRate":0.0159288537549408,"floatShares":7767933,"shares":7991799,"eps":-7.4139,"marketStatus":"交易中","change":0.0403,"latestTime":"07-31 14:01:46 EDT","open":2.6,"high":2.6,"low":2.51,"amount":57191.43395880001,"amplitude":0.035573,"askPrice":2.6,"askSize":5,"bidPrice":2.55,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-7.4139,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1785528000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":2.53,"preHourTrading":{"tag":"盘前","latestPrice":2.58,"preClose":2.53,"latestTime":"09:29 EDT","volume":958,"amount":2467.6885374,"timestamp":1785504599999,"change":0.05,"changeRate":0.019763,"amplitude":0.054743},"postHourTrading":{"tag":"盘后","latestPrice":2.64,"preClose":2.53,"latestTime":"19:56 EDT","volume":111,"amount":291.83,"timestamp":1785455785047,"change":0.11,"changeRate":0.043478,"amplitude":0.043478},"volumeRatio":0.703158,"impliedVol":1.1856,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/CLRB","defaultTab":"news","newsList":[{"id":"1112433397","title":"Cellectar Biosciences Inc. 提交文件，拟由售股股东发行至多5120万股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1112433397","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112433397?lang=zh_cn&edition=full","pubTime":"2026-05-20 05:09","pubTimestamp":1779224951,"startTime":"0","endTime":"0","summary":"Cellectar Biosciences Inc. 已向美国证券交易委员会提交相关文件，计划由售股股东发行至多5120万股普通股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121673150","title":"Cellectar Biosciences公布2B期Clover Wam研究12个月随访数据 Iopofosine I 131在R/R华氏巨球蛋白血症中展现持久疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1121673150","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121673150?lang=zh_cn&edition=full","pubTime":"2026-05-05 19:13","pubTimestamp":1777979585,"startTime":"0","endTime":"0","summary":"Cellectar Biosciences公司最新发布的2B期Clover Wam研究12个月随访数据证实，其核心候选药物Iopofosine I 131在治疗复发/难治性华氏巨球蛋白血症（R/R WM）领域展现出持久的治疗反应与显著的临床疗效。\n长期随访结果进一步验证了该放射性药物治疗方案的潜力，为这类罕见血液恶性肿瘤患者提供了新的希望。数据显示，接受治疗的患者在12个月观察期内持续产生深度缓解，药物安全性特征与早期研究结果保持一致。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121969203","title":"Cellectar Biosciences 推进在BTK抑制剂治疗后一线患者中启动验证性随机研究计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1121969203","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121969203?lang=zh_cn&edition=full","pubTime":"2026-05-05 19:12","pubTimestamp":1777979576,"startTime":"0","endTime":"0","summary":"Cellectar Biosciences Inc. (CLRB) 正积极推进其临床开发战略，计划在一线治疗失败且已接受过BTK抑制剂治疗的患者群体中，启动一项关键的验证性随机研究。这项研究旨在进一步评估其核心疗法的有效性与安全性，为该药物在更广泛临床场景中的应用提供坚实证据。\n公司此举标志着其研发管线的重要进展，目标是为现有治疗方案有限的难治性患者群体探索新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108350779","title":"Cellectar Biosciences公布二期CLOVER WAM试验结果：客观缓解率达83.6%，主要缓解率61.8%，中位缓解持续时间17.8个月","url":"https://stock-news.laohu8.com/highlight/detail?id=1108350779","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108350779?lang=zh_cn&edition=full","pubTime":"2026-05-05 19:11","pubTimestamp":1777979506,"startTime":"0","endTime":"0","summary":"在备受瞩目的二期CLOVER WAM临床试验中，Cellectar Biosciences Inc.交出了一份亮眼的成绩单。数据显示，该试验取得了83.6%的客观缓解率（ORR）和61.8%的主要缓解率（MRR），尤为突出的是，患者的中位缓解持续时间达到了17.8个月。\n这一系列积极数据显著超越了既定目标，为该公司在研疗法的有效性和持久性提供了强有力的证据。长久的缓解持续时间，尤其预示着该疗法可能为患者带来更具实质性的临床获益。\n试验结果的公布，无疑为Cellectar Biosciences的未来发展注入了强劲动力，也使其在竞争激烈的生物技术领域占据了更为有利的位置。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156897620","title":"Cellectar Biosciences Inc. 完成新一轮融资，由Nantahala Capital领投，多家知名医疗投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=1156897620","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156897620?lang=zh_cn&edition=full","pubTime":"2026-05-05 19:10","pubTimestamp":1777979451,"startTime":"0","endTime":"0","summary":"Cellectar Biosciences Inc. (CLRB) 成功完成一轮融资，本轮融资由Nantahala Capital Management, LLC 领投。值得注意的是，数家大型医疗健康领域的专业投资机构也参与了此次投资，显示出市场对Cellectar Biosciences Inc. 发展前景的强烈信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191144393","title":"Cellectar Biosciences宣布Clover Wam临床试验数据子集获选2026年美国临床肿瘤学会年会展示","url":"https://stock-news.laohu8.com/highlight/detail?id=1191144393","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191144393?lang=zh_cn&edition=full","pubTime":"2026-04-21 22:00","pubTimestamp":1776780016,"startTime":"0","endTime":"0","summary":"Cellectar Biosciences公司近日披露，其Clover Wam临床试验的部分数据已被正式接收，将于2026年美国临床肿瘤学会（ASCO）年会上进行专题报告。这一进展标志着该创新疗法在肿瘤治疗领域的重要突破获得国际权威学术平台的认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108470462","title":"Cellectar启动首例患者入组 开展针对难治性三阴性乳腺癌的CLR 125奥杰发射放射性偶联物1B期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1108470462","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108470462?lang=zh_cn&edition=full","pubTime":"2026-04-14 20:38","pubTimestamp":1776170287,"startTime":"0","endTime":"0","summary":"Cellectar Biosciences公司宣布，其针对难治性三阴性乳腺癌的CLR 125奥杰发射放射性偶联物已启动1B期临床试验，并完成首例患者入组。这项重要进展标志着该创新疗法在临床开发道路上迈出关键一步。\nCLR 125作为靶向放射治疗药物，采用奥杰电子发射技术精准作用于癌细胞。三阴性乳腺癌作为最具侵袭性的乳腺癌亚型，治疗选择有限，该试验旨在为这类患者探索新的治疗可能。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616755321","title":"Cellectar Biosciences, Inc.盘中异动 大幅下跌7.86%报2.99美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616755321","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616755321?lang=zh_cn&edition=full","pubTime":"2026-03-03 01:50","pubTimestamp":1772473800,"startTime":"0","endTime":"0","summary":"北京时间2026年03月03日01时50分，Cellectar Biosciences, Inc.股票出现异动，股价急速下挫7.86%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.58%。其相关个股中，Aspire Biopharma Holdings Inc C/Wts 14/02/2030 、Rallybio Corporation、Anebulo Pharmaceuticals, Inc.涨幅较大，Ensysce Biosciences, Inc.、Cardio Diagnostics Holdings Inc.、Rallybio Corporation较为活跃，换手率分别为154.43%、92.51%、53.62%，振幅较大的相关个股有Lyra Therapeutics, Inc.、Anebulo Pharmaceuticals, Inc.、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com，振幅分别为53.84%、38.89%、31.86%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603030150009542a753&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603030150009542a753&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PDC","BK4139","CLRB","BK4123"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614867148","title":"Cellectar Biosciences, Inc.盘中异动 急速下挫5.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614867148","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614867148?lang=zh_cn&edition=full","pubTime":"2026-02-28 00:29","pubTimestamp":1772209796,"startTime":"0","endTime":"0","summary":"北京时间2026年02月28日00时29分，Cellectar Biosciences, Inc.股票出现异动，股价快速下跌5.41%。截至发稿，该股报3.32美元/股，成交量5520股，换手率0.13%，振幅3.99%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.95%。其相关个股中，Ensysce Biosciences, Inc.、Edesa Biotech, Inc.、Neurogene Inc.涨幅较大，Ensysce Biosciences, Inc.、Cardio Diagnostics Holdings Inc.、Edesa Biotech, Inc.较为活跃，换手率分别为6195.78%、555.22%、224.13%，振幅较大的相关个股有Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Edesa Biotech, Inc.、Ensysce Biosciences, Inc.，振幅分别为76.88%、60.64%、51.85%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022800295695424d8d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022800295695424d8d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CLRB","BK4139","PDC","BK4123"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610667714","title":"Cellectar Biosciences, Inc.盘中异动 快速拉升5.26%报3.20美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610667714","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610667714?lang=zh_cn&edition=full","pubTime":"2026-02-10 01:35","pubTimestamp":1770658515,"startTime":"0","endTime":"0","summary":"北京时间2026年02月10日01时35分，Cellectar Biosciences, Inc.股票出现异动，股价大幅上涨5.26%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.56%。其相关个股中，Moolec Science Sa C/Wts 30/01/2028、Humacyte, Inc.、Tuhura Biosciences, Inc.涨幅较大，Agomab Therapeutics Nv、Liminatus Pharma, Inc.、Aim Immunotech Inc.较为活跃，换手率分别为325.30%、181.27%、29.54%，振幅较大的相关个股有Moolec Science Sa C/Wts 30/01/2028、Liminatus Pharma Inc C/Wts 30/04/2030 、Liminatus Pharma, Inc.，振幅分别为59.15%、52.99%、51.63%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210013516a6e6fa5a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210013516a6e6fa5a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PDC","BK4123","CLRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518224030","title":"Cellectar Biosciences, Inc.盘中异动 大幅上涨5.79%报0.336美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518224030","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518224030?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:38","pubTimestamp":1741613933,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时38分，Cellectar Biosciences, Inc.股票出现异动，股价大幅上涨5.79%。截至发稿，该股报0.336美元/股，成交量29.5357万股，换手率0.64%，振幅5.53%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.41%。其相关个股中，Trevi Therapeutics, Inc.、Checkpoint Therapeutics, Inc.、Scisparc Ltd.涨幅较大，Scisparc Ltd.、Dogwood Therapeutics, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为482.63%、74.60%、55.47%，振幅较大的相关个股有Seer, Inc.、Scisparc Ltd.、Impact Biomedical, Inc.，振幅分别为98.72%、34.57%、25.80%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021385398a29e82&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021385398a29e82&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CLRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517167845","title":"Cellectar Biosciences, Inc.盘中异动 早盘股价大涨5.37%报0.320美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517167845","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517167845?lang=zh_cn&edition=full","pubTime":"2025-03-07 00:09","pubTimestamp":1741277382,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日00时09分，Cellectar Biosciences, Inc.股票出现异动，股价大幅上涨5.37%。截至发稿，该股报0.320美元/股，成交量22.5693万股，换手率0.49%，振幅7.28%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.29%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000942a262a80a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000942a262a80a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CLRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517677945","title":"Cellectar Biosciences, Inc.盘中异动 早盘大幅上涨5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517677945","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517677945?lang=zh_cn&edition=full","pubTime":"2025-03-05 23:00","pubTimestamp":1741186827,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日23时00分，Cellectar Biosciences, Inc.股票出现波动，股价快速拉升5.26%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为1.27%。其相关个股中，Chimerix, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Nutriband Inc C/Wts 涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为722.68%、276.27%、237.00%，振幅较大的相关个股有Nkgen Biotech, Inc.、180 Life Sciences Corp C/Wts 07/11/2025、Silexion Therapeutics Corp，振幅分别为40.77%、36.89%、33.33%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305230027abe9ba43&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305230027abe9ba43&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CLRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516637894","title":"Cellectar Biosciences, Inc.盘中异动 早盘股价大涨5.08%报0.304美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516637894","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516637894?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:47","pubTimestamp":1741013272,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时47分，Cellectar Biosciences, Inc.股票出现异动，股价快速拉升5.08%。截至发稿，该股报0.304美元/股，成交量10.2894万股，换手率0.22%，振幅2.73%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.05%。其相关个股中，Bioxcel Therapeutics, Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Geovax Labs, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为346.65%、109.40%、66.34%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Geovax Labs Inc C/Wts 29/09/2025，振幅分别为140.46%、68.30%、24.83%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032247529637b100&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032247529637b100&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CLRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514850662","title":"Cellectar Biosciences, Inc.盘中异动 大幅拉升5.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514850662","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514850662?lang=zh_cn&edition=full","pubTime":"2025-02-27 00:40","pubTimestamp":1740588037,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日00时40分，Cellectar Biosciences, Inc.股票出现波动，股价快速上涨5.57%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.02%。其相关个股中，Enveric Biosciences, Inc.、Pds Biotechnology Corporation、Renovaro Inc.涨幅较大，Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为5929.07%、215.68%、215.55%，振幅较大的相关个股有Enveric Biosciences, Inc.、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Organovo Holdings, Inc.，振幅分别为181.36%、49.18%、43.31%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502270040379893c314&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502270040379893c314&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CLRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514905560","title":"Cellectar Biosciences, Inc.盘中异动 股价大涨5.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514905560","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514905560?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:31","pubTimestamp":1740493879,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时31分，Cellectar Biosciences, Inc.股票出现异动，股价大幅上涨5.46%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.36%。其相关个股中，Organovo Holdings, Inc.、Moleculin Biotech, Inc.、Silexion Therapeutics Corp涨幅较大，Gt Biopharma, Inc.、Organovo Holdings, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为748.35%、529.64%、461.94%，振幅较大的相关个股有Organovo Holdings, Inc.、Adial Pharmaceuticals, Inc、Maze Therapeutics, Inc.，振幅分别为43.36%、19.20%、8.87%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022522312098924c5f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022522312098924c5f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CLRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514705674","title":"Cellectar Biosciences, Inc.盘中异动 临近收盘股价大跌5.56%报0.294美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514705674","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514705674?lang=zh_cn&edition=full","pubTime":"2025-02-25 04:57","pubTimestamp":1740430678,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日04时57分，Cellectar Biosciences, Inc.股票出现异动，股价急速下跌5.56%。截至发稿，该股报0.294美元/股，成交量65.8749万股，换手率1.43%，振幅4.98%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.40%。其相关个股中，Nutriband Inc C/Wts 、Pepgen Inc.、Surrozen Inc C/Wts 01/08/2031 涨幅较大，Pepgen Inc.、Aditxt, Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为333.01%、145.74%、41.82%，振幅较大的相关个股有Nutriband Inc C/Wts 、Pepgen Inc.、Surrozen Inc C/Wts 01/08/2031 ，振幅分别为176.22%、164.23%、81.92%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225045759a2526493&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225045759a2526493&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CLRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513347219","title":"Cellectar Biosciences, Inc.盘中异动 下午盘股价大跌5.53%报0.316美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513347219","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513347219?lang=zh_cn&edition=full","pubTime":"2025-02-22 03:04","pubTimestamp":1740164660,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日03时04分，Cellectar Biosciences, Inc.股票出现波动，股价快速下跌5.53%。截至发稿，该股报0.316美元/股，成交量50.4275万股，换手率1.09%，振幅7.75%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.37%。其相关个股中，Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Revolution Medicines Inc C/Wts 17/12/2026 、Invivyd, Inc.涨幅较大，Aditxt, Inc.、Nkgen Biotech, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为298.79%、247.85%、136.62%，振幅较大的相关个股有Osr Holdings, Inc.、Invivyd, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028，振幅分别为76.52%、70.25%、61.26%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222030420a24ee874&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222030420a24ee874&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CLRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512416530","title":"Cellectar Biosciences, Inc.盘中异动 早盘大幅拉升7.50%报0.313美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512416530","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512416530?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:32","pubTimestamp":1739889131,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时32分，Cellectar Biosciences, Inc.股票出现异动，股价快速上涨7.50%。截至发稿，该股报0.313美元/股，成交量9.5016万股，换手率0.21%，振幅0.00%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.11%。其相关个股中，Solid Biosciences Inc.、Revolution Medicines Inc C/Wts 17/12/2026 、Glycomimetics, Inc.涨幅较大，Aditxt, Inc.、Solid Biosciences Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为276.23%、91.16%、60.68%，振幅较大的相关个股有Allogene Therapeutics, Inc.、Cns Pharmaceuticals, Inc.、Allakos Inc.，振幅分别为9.56%、8.57%、8.35%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218223211a24aacc1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218223211a24aacc1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CLRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511611737","title":"Cellectar Biosciences, Inc.盘中异动 股价大涨5.91%报0.298美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511611737","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511611737?lang=zh_cn&edition=full","pubTime":"2025-02-15 03:34","pubTimestamp":1739561694,"startTime":"0","endTime":"0","summary":"北京时间2025年02月15日03时34分，Cellectar Biosciences, Inc.股票出现波动，股价急速拉升5.91%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.62%。其相关个股中，Moleculin Biotech, Inc.、Nls Pharmaceutics Ltd C/Wts 02/02/2026、Allogene Therapeutics, Inc.涨幅较大，Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Virpax Pharmaceuticals, Inc.较为活跃，换手率分别为3108.86%、792.24%、617.89%，振幅较大的相关个股有Lexaria Bioscience Corp C/Wts 14/01/2026 、Moleculin Biotech, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 ，振幅分别为74.35%、71.65%、66.45%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250215033454abcf45fd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250215033454abcf45fd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CLRB"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cellectar.com","stockEarnings":[{"period":"1week","weight":0.0243},{"period":"1month","weight":-0.0899},{"period":"3month","weight":-0.0595},{"period":"6month","weight":-0.2143},{"period":"1year","weight":-0.4707},{"period":"ytd","weight":-0.1424}],"compareEarnings":[{"period":"1week","weight":0.0048},{"period":"1month","weight":-0.0068},{"period":"3month","weight":0.0292},{"period":"6month","weight":0.0719},{"period":"1year","weight":0.169},{"period":"ytd","weight":0.0876}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Cellectar Biosciences, Inc.以前名为Novelos Therapeutics, Inc.于1996年6月成立于特拉华州。2014年2月11日，公司更名为现在的名字。该公司是一家后期临床生物制药公司，专注于癌症治疗药物的发现、开发和商业化。该公司的核心目标是利用专有的磷脂醚药物偶联物递送平台开发PDC，这些PDC旨在专门针对癌细胞，并由于更少的脱靶效应而提供更好的功效和更好的安全性。","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.017624},{"month":2,"riseRate":0.666667,"avgChangeRate":0.024048},{"month":3,"riseRate":0.5,"avgChangeRate":-0.034403},{"month":4,"riseRate":0.25,"avgChangeRate":-0.094306},{"month":5,"riseRate":0.416667,"avgChangeRate":0.057843},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.0753},{"month":7,"riseRate":0.25,"avgChangeRate":-0.095767},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.013426},{"month":9,"riseRate":0.416667,"avgChangeRate":-0.024755},{"month":10,"riseRate":0.083333,"avgChangeRate":-0.159758},{"month":11,"riseRate":0.416667,"avgChangeRate":-0.062866},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.062943}],"exchange":"NASDAQ","name":"Cellectar Biosciences Inc.","nameEN":"Cellectar Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cellectar Biosciences Inc.(CLRB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Cellectar Biosciences Inc.(CLRB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Cellectar Biosciences Inc.,CLRB,Cellectar Biosciences Inc.股票,Cellectar Biosciences Inc.股票老虎,Cellectar Biosciences Inc.股票老虎国际,Cellectar Biosciences Inc.行情,Cellectar Biosciences Inc.股票行情,Cellectar Biosciences Inc.股价,Cellectar Biosciences Inc.股市,Cellectar Biosciences Inc.股票价格,Cellectar Biosciences Inc.股票交易,Cellectar Biosciences Inc.股票购买,Cellectar Biosciences Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cellectar Biosciences Inc.(CLRB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Cellectar Biosciences Inc.(CLRB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}